These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34287384)

  • 41. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study.
    Santos CVBD; Valiati NCM; Noronha TG; Porto VBG; Pacheco AG; Freitas LP; Coelho FC; Gomes MFDC; Bastos LS; Cruz OG; Lana RM; Luz PM; Carvalho LMF; Werneck GL; Struchiner CJ; Villela DAM
    Lancet Reg Health Am; 2023 Apr; 20():100465. PubMed ID: 36936517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
    Costa Clemens SA; Marchevsky N; Kelly S; Felle S; Eldawi A; Rajasingam R; Mahmud R; Lambe T; Voysey M; Gonzalez I; Milan EP; Justino MC; Bibi S; Aley P; Clemens R; Pollard AJ
    Hum Vaccin Immunother; 2023 Aug; 19(2):2233400. PubMed ID: 37438960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers.
    Jantarabenjakul W; Chantasrisawad N; Puthanakit T; Wacharapluesadee S; Hirankarn N; Ruenjaiman V; Paitoonpong L; Suwanpimolkul G; Torvorapanit P; Pradit R; Sophonphan J; Putcharoen O
    Asian Pac J Allergy Immunol; 2022 Sep; 40(3):269-277. PubMed ID: 34717527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths.
    Meo SA; Aftab S; Bayoumy NM; Meo AS
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10133-10143. PubMed ID: 37916383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients.
    Torres R; Toro L; Sanhueza ME; Lorca E; Ortiz M; Pefaur J; Clavero R; Machuca E; Gonzalez F; Herrera P; Mocarquer A; Frias A; Roessler E; Muñoz C; Nuñez M; Aravena C; Quintana E; Lemus J; Lillo M; Reynolds E; Morales A; Pais E; Fiabane A; Parra-Lucares A; Garrido C; Mendez-Valdes G; Villa E; Mansilla R; Sotomayor G; Gonzalez M; Miranda C; Briones E; Gomez E; Mezzano S; Bernales W; Rocca X; Espinoza O; Zuñiga E; Aragon H; Badilla M; Valenzuela M; Escobar L; Zamora D; Flores I; Tapia B; Borquez T; Herrera P
    Kidney Int Rep; 2022 Oct; 7(10):2176-2185. PubMed ID: 35874643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expert review on global real-world vaccine effectiveness against SARS-CoV-2.
    Chuenkitmongkol S; Solante R; Burhan E; Chariyalertsak S; Chiu NC; Do-Van D; Husin M; Hwang KP; Kiertiburanakul S; Kulkarni PS; Lee PI; Lobo RC; Nghia CH; Ong-Lim A; Sivasampu S; Suah JL; Tok PSK; Thwaites G;
    Expert Rev Vaccines; 2022 Sep; 21(9):1255-1268. PubMed ID: 35748494
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Wittmann I; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Polivka L; Pálosi M; Szlávik J; Rokszin G; Müller C; Szekanecz Z; Kásler M
    Front Immunol; 2022; 13():919408. PubMed ID: 35935993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
    Li JX; Wu SP; Guo XL; Tang R; Huang BY; Chen XQ; Chen Y; Hou LH; Liu JX; Zhong J; Pan HX; Shi FJ; Xu XY; Li ZP; Zhang XY; Cui LB; Tan WJ; Chen W; Zhu FC;
    Lancet Respir Med; 2022 Aug; 10(8):739-748. PubMed ID: 35605625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.
    Zhao S; Guo Z; Sun S; Hung CT; Leung EYM; Wei Y; Wang H; Li K; Yam CHK; Chow TY; Gao J; Jia KM; Chong KC; Yeoh EK
    J Clin Virol; 2023 Sep; 166():105547. PubMed ID: 37453162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of antibody response after two doses of the Sinovac vaccine and the potential need for booster doses in cancer patients.
    Ata S; Cil T; Duman BB; Unal N
    J Med Virol; 2022 Jun; 94(6):2487-2492. PubMed ID: 35181932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
    Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
    EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
    Smith DJ; Hakim AJ; Leung GM; Xu W; Schluter WW; Novak RT; Marston B; Hersh BS
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(15):545-548. PubMed ID: 35421076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The hindrances to perform the COVID-19 vaccination in Brazil.
    Boschiero MN; Palamim CVC; Marson FAL
    Hum Vaccin Immunother; 2021 Nov; 17(11):3989-4004. PubMed ID: 34353218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand.
    Hongjaisee S; Chawansuntati K; Sripan P; Rattanathammethee K; Sakkhachornphop S; Chaiwarith R; Sudjaritruk T; Supparatpinyo K; Wipasa J
    Vaccine X; 2023 Aug; 14():100305. PubMed ID: 37155476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.